In a post hoc analysis of patients
with cellulitis with or without an abscess at another
site, the cure rates were 87.9% (138 of 157
patients) with TMP-SMX and 90.9% (149 of 164)
with clindamycin in the population that could
be evaluated (difference, −3.0 percentage points
[95% CI, −10.5 to 4.6]) and 77.1% (138 of 179)
and 81.4% (149 of 183), respectively, in the intention-
to-treat population (difference, −4.3 percentage
points [95% CI, −13.5 to 4.8]). Our study was
not powered to determine the superiority of one
agent over the other in the subgroup of patients
with cellulitis, but the data suggest that if there
is a difference in outcome it is probably small.